Litcius/Paper detail

Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079)

Terumi Tanigawa, Nobuhiro Takeshima, Hideki Ishikawa, Shin Nishio, Tomoka Usami, Takaharu Yamawaki, Tetsuro Oishi, Kei Ihira, Hisamori Kato, Mayako Goto, Motoaki Saito, Yusuke Taira, Masatoshi Yokoyama, Tadahiro Shoji, Eiji Kondo, Atsushi Mori, Takeshi Yokoi, Naomi Iwasa-Inoue, Yasuyuki Hirashima, Takayuki Nagasawa, Motoki Takenaka, Mikio Mikami, Toru Sugiyama, Takayuki Enomoto

2022Gynecologic Oncology15 citationsDOI

Topics & Concepts

MedicineBevacizumabCarboplatinClinical endpointSurgeryInternal medicineRadiation therapyCervical cancerMaintenance therapyChemotherapyPaclitaxelPhases of clinical researchOncologyResponse Evaluation Criteria in Solid TumorsCancerClinical trialCisplatinEndometrial and Cervical Cancer TreatmentsCervical Cancer and HPV ResearchBioactive Compounds and Antitumor Agents
Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079) | Litcius